IBDEI10H ; ; 01-FEB-2022
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,16451,0)
 ;;=I09.89^^61^774^17
 ;;^UTILITY(U,$J,358.3,16451,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16451,1,3,0)
 ;;=3^Rheumatic Heart Diseases NEC
 ;;^UTILITY(U,$J,358.3,16451,1,4,0)
 ;;=4^I09.89
 ;;^UTILITY(U,$J,358.3,16451,2)
 ;;=^5007060
 ;;^UTILITY(U,$J,358.3,16452,0)
 ;;=I47.1^^61^774^24
 ;;^UTILITY(U,$J,358.3,16452,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16452,1,3,0)
 ;;=3^Supraventricular Tachycardia
 ;;^UTILITY(U,$J,358.3,16452,1,4,0)
 ;;=4^I47.1
 ;;^UTILITY(U,$J,358.3,16452,2)
 ;;=^5007223
 ;;^UTILITY(U,$J,358.3,16453,0)
 ;;=I48.0^^61^774^15
 ;;^UTILITY(U,$J,358.3,16453,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16453,1,3,0)
 ;;=3^Paroxysmal Atrial Fibrillation
 ;;^UTILITY(U,$J,358.3,16453,1,4,0)
 ;;=4^I48.0
 ;;^UTILITY(U,$J,358.3,16453,2)
 ;;=^90473
 ;;^UTILITY(U,$J,358.3,16454,0)
 ;;=I49.5^^61^774^23
 ;;^UTILITY(U,$J,358.3,16454,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16454,1,3,0)
 ;;=3^Sick Sinus Syndrome
 ;;^UTILITY(U,$J,358.3,16454,1,4,0)
 ;;=4^I49.5
 ;;^UTILITY(U,$J,358.3,16454,2)
 ;;=^110404
 ;;^UTILITY(U,$J,358.3,16455,0)
 ;;=I49.8^^61^774^3
 ;;^UTILITY(U,$J,358.3,16455,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16455,1,3,0)
 ;;=3^Cardiac Arrhythmias
 ;;^UTILITY(U,$J,358.3,16455,1,4,0)
 ;;=4^I49.8
 ;;^UTILITY(U,$J,358.3,16455,2)
 ;;=^5007236
 ;;^UTILITY(U,$J,358.3,16456,0)
 ;;=I49.9^^61^774^2
 ;;^UTILITY(U,$J,358.3,16456,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16456,1,3,0)
 ;;=3^Cardiac Arrhythmia,Unspec
 ;;^UTILITY(U,$J,358.3,16456,1,4,0)
 ;;=4^I49.9
 ;;^UTILITY(U,$J,358.3,16456,2)
 ;;=^5007237
 ;;^UTILITY(U,$J,358.3,16457,0)
 ;;=R00.1^^61^774^1
 ;;^UTILITY(U,$J,358.3,16457,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16457,1,3,0)
 ;;=3^Bradycardia,Unspec
 ;;^UTILITY(U,$J,358.3,16457,1,4,0)
 ;;=4^R00.1
 ;;^UTILITY(U,$J,358.3,16457,2)
 ;;=^5019164
 ;;^UTILITY(U,$J,358.3,16458,0)
 ;;=I34.1^^61^774^14
 ;;^UTILITY(U,$J,358.3,16458,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16458,1,3,0)
 ;;=3^Nonrheumatic Mitral Valve Prolapse
 ;;^UTILITY(U,$J,358.3,16458,1,4,0)
 ;;=4^I34.1
 ;;^UTILITY(U,$J,358.3,16458,2)
 ;;=^5007170
 ;;^UTILITY(U,$J,358.3,16459,0)
 ;;=D68.4^^61^775^1
 ;;^UTILITY(U,$J,358.3,16459,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16459,1,3,0)
 ;;=3^Acquired Coagulation Factor Deficiency
 ;;^UTILITY(U,$J,358.3,16459,1,4,0)
 ;;=4^D68.4
 ;;^UTILITY(U,$J,358.3,16459,2)
 ;;=^2235
 ;;^UTILITY(U,$J,358.3,16460,0)
 ;;=D59.9^^61^775^2
 ;;^UTILITY(U,$J,358.3,16460,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16460,1,3,0)
 ;;=3^Acquired Hemolytic Anemia,Unspec
 ;;^UTILITY(U,$J,358.3,16460,1,4,0)
 ;;=4^D59.9
 ;;^UTILITY(U,$J,358.3,16460,2)
 ;;=^5002330
 ;;^UTILITY(U,$J,358.3,16461,0)
 ;;=C91.00^^61^775^5
 ;;^UTILITY(U,$J,358.3,16461,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16461,1,3,0)
 ;;=3^Acute Lymphoblastic Leukemia,Not in Remission
 ;;^UTILITY(U,$J,358.3,16461,1,4,0)
 ;;=4^C91.00
 ;;^UTILITY(U,$J,358.3,16461,2)
 ;;=^5001762
 ;;^UTILITY(U,$J,358.3,16462,0)
 ;;=C91.01^^61^775^4
 ;;^UTILITY(U,$J,358.3,16462,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16462,1,3,0)
 ;;=3^Acute Lymphoblastic Leukemia,In Remission
 ;;^UTILITY(U,$J,358.3,16462,1,4,0)
 ;;=4^C91.01
 ;;^UTILITY(U,$J,358.3,16462,2)
 ;;=^5001763
 ;;^UTILITY(U,$J,358.3,16463,0)
 ;;=C92.01^^61^775^7
 ;;^UTILITY(U,$J,358.3,16463,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16463,1,3,0)
 ;;=3^Acute Myeloblastic Leukemia,In Remission
